The new study re-analyzed data from three pivotal TB trials that had failed to show the efficacy of four-month treatments over the standard six-month duration

BD MAX™ MDR-TB Panel obtains CE-IVD status in Europe

Game-changing study on treatment of latent Tuberculosis shows a novel, short therapy is safer and more effective in children and adults than standard therapy

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against Tuberculosis, the world's leading infectious disease killer